Showing 401-410 of 3378 results for "".
Do This Now: Be a Better Leader
https://practicaldermatology.com/topics/practice-management/do-this-now-be-a-better-leader/19111/Speaking at the Vegas Cosmetic Dermatology meeting, Todd E. Schlesinger, MD shares tips for becoming a better leader in your aesthetics practice--whether you own the practice or not. Understanding personalities and leading outside the practice walls are key.Merz Acquires Ulthera; Ulthera Gets Decolletage Indication, and a New Topical for Onychomycosis
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-merz-acquires-ulthera-ulthera-gets-decolletage-indication-and-a-new-topical-for-onychomycosis/19117/In this edition of DermWireTV, from the publishers of Practical Dermatology® magazine, learn the latest on the Merz/Ulthera acquisition, a new topical for toenail fungus, and FDA accepts Kythera's NDA.Electronic Health Records
https://practicaldermatology.com/topics/practice-management/electronic-health-records/19383/Dr. Kaufmann discusses EHRs, government incentives, and the importance of choosing a system that is right for each practice. He offers tips for residents and young physicians for choosing and using electronic health records.Psoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study
https://practicaldermatology.com/topics/psoriasis/psoriasis-pipeline-update-jnj-2113-a-novel-oral-il-23-receptor-antagonist-peptide-shows-promise-in-a-phase-2b-study/20207/Laura Korb Ferris, MD, PhD, discusses the topline results from a Phase 2b trial of JNJ-2113, a novel oral IL-23 receptor antagonist peptide that’s being developed for moderate-to-severe plaque psoriasis.FDA Approves New Drug for Prurigo Nodularis; Long-Term Use of Dupilumab Examined
https://practicaldermatology.com/series/dermwire-tv/fda-approves-new-drug-prurigo-nodularis-long-term-use-dupilumab-examined/26925/In this week's DermwireTV, the FDA approves Galderma's Nemluvio for adults with prurigo nodularis; a study examines the long-term use of dupilumab for atopic dermatitis; and Andrew Mastro discusses how to talk to patients about starting a Janus kinase (JAK) inhibitor for AD.FDA Approves Axillary Hyperhidrosis Treatment; Study Examines Biologic Outcomes in Psoriasis
https://practicaldermatology.com/series/dermwire-tv/fda-approves-axillary-hyperhidrosis-treatment-study-examines-biologic-outcomes-psoriasis/26562/In this week's DermwireTV, the FDA approves a first-of-its-kind gel for axillary hyperhidrosis; a new analysis examines how smoking, BMI, and age affect biologic outcomes in psoriasis; and the CEO of Aerolase joins us to discuss the latest trends in the aesthetic laser market.New Analysis of Benzene Contamination in BPO Products
https://practicaldermatology.com/series/dermwire-tv/new-analysis-benzene-contamination-bpo-products/29074/In this week's DermwireTV, new data continues to raise concerns about benzene contamination in BPO products; the FDA expands the approved dosage for Ameluz for actinic keratosis (AK); and in our PA Perspectives segment, Andrew Mastro discusses how to approach a contract negotiation.Cutaneous Oncology in 2024
https://practicaldermatology.com/conferences/maui-derm-2024/cutaneous-oncology-in-2024/20266/Resident Of Distinction Award-winner Banu Farabi, MD, a PGY-3 resident at New York Medical College, talks about a review she attended highlighting the latest therapeutic approaches to treating conditions such as actinic keratosis and several different types of skin cancer, as well as an overview ofResidents' Reports: A Comparison of Fractional Resurfacing Lasers
https://practicaldermatology.com/topics/general-topics/residents-reports-a-comparison-of-fractional-resurfacing-lasers/21966/Practitioners considering an investment in resurfacing lasers may benefit from this comparison of key system features.Journal Club: Combining Dupilumab and Omalizumab
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-combining-dupilumab-and-omalizumab/37872/Practical Dermatology chief medical editor Neal Bhatia, MD, FAAD, and editorial board member Brad Glick, DO, MPH, FAAD, discuss a recent article about combination therapy with dupilumab and omalizumab for atopic dermatitis. Silva IC, Daher R, Khattri S. Combined use of Omalizumab and dupilumab